BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 2:51:00 PM | Browse: 1092 | Download: 993
Publication Name World Journal of Gastroenterology
Manuscript ID 5781
Country/Territory Taiwan
Received
2013-09-25 21:51
Peer-Review Started
2013-09-27 08:18
To Make the First Decision
2013-12-26 10:56
Return for Revision
2013-10-16 14:33
Revised
2013-10-25 10:42
Second Decision
2014-01-15 20:21
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-01-15 20:37
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-03-01 18:10
Publish the Manuscript Online
2014-03-18 14:14
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection
Manuscript Source Invited Manuscript
All Author List Chun-Jen Liu and Pei-Jer Chen
Funding Agency and Grant Number
Funding Agency Grant Number
National Taiwan University
Department of Health, Executive Yuan, Taiwan
Taiwan Liver Disease Consortium (TLC), National Research Program for Biopharmaceuticals (NRPB), Taiwan NSC100-2325-B-002-052
Corresponding Author Pei-Jer Chen, MD, PhD, Distinguished Professor, Graduate Institute of Clinical Medicine, Department of Internal Medicine, and Hepatitis Research Center, National Taiwan University College of Medicine and National Taiwan University Hospital, Chang-Te Street, Taipei 10002, Taiwan. peijerchen@ntu.edu.tw
Key Words Dual infection; Hepatitis B virus; Hepatitis C virus; Interferon; Pegylated interferon; Ribavirin; Sustained virological response; Hepatitis B surface antigen clearance
Core Tip Patients with dual hepatitis C virus (HCV)/hepatitis B virus (HBV) infections have a higher risk of liver disease progression compared with patients with HBV or HCV monoinfections. The combination peginterferon alpha/ribavirin treatment for dual hepatitis patients with HCV dominance appears to be just as effective in the clearance of HCV RNA and safe as it is in patients with HCV monoinfections. The durability of HCV response was 97%. Furthermore, approximately 30% of dually infected patients lost hepatitis B surface antigen within 5 years after the start of peginterferon-based therapy. A population-based study revealed the benefits of combination therapy in the improvement of long-term outcomes in dually infected patients.
Publish Date 2014-03-18 14:14
Citation Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20(11): 2955-2961
URL http://www.wjgnet.com/1007-9327/full/v20/i11/2955.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i11.2955
Full Article (PDF) WJG-20-2955.pdf
Full Article (Word) WJG-20-2955.doc
Manuscript File 5781-Review.doc
Answering Reviewers 5781-Answering reviewers.pdf
Copyright License Agreement 5781-Copyright agreement.pdf
Non-Native Speakers of English Editing Certificate 5781-Language certificate.pdf
Peer-review Report 5781-Peer reviews.pdf
Scientific Editor Work List 5781-Scientific editor work list.doc